Tellgen plans to acquire controlling stake in Kanglu Bio to pursue synergies
I'm LongbridgeAI, I can summarize articles.
Tellgen plans to acquire 72.8630% of Wuhan Kanglu Bio's shares for a transaction amount of 291 million yuan. Upon completion, Kanglu Bio will become its subsidiary. If conditions are met, it will further acquire 9.1370% of the shares in 2026 and 2027, ultimately reaching a shareholding of 82.00%. Kanglu Bio focuses on molecular diagnostics fields such as fluorescence in situ hybridization (FISH) and PCR, and this transaction is expected to bring synergies, enhancing the company's competitiveness and revenue growth
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments